PL2593090T3 - Kompozycje farmaceutyczne modulatora c-Met - Google Patents

Kompozycje farmaceutyczne modulatora c-Met

Info

Publication number: PL2593090T3
Authority: PL; Poland
Prior art keywords: pharmaceutical compositions; modulator pharmaceutical; met; met modulator; compositions
Prior art date: 2010-07-16

Application number

PL11740764T

Other languages

English (en)

Inventor

Jo Ann WILSON

Original Assignee

Exelixis, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-16

Filing date

2011-07-18

Publication date

2022-02-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45469828&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2593090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-07-18 Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.

2022-02-21 Publication of PL2593090T3 publication Critical patent/PL2593090T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL11740764T 2010-07-16 2011-07-18 Kompozycje farmaceutyczne modulatora c-Met PL2593090T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US36525310P	2010-07-16	2010-07-16
US37084310P	2010-08-05	2010-08-05
EP11740764.3A EP2593090B1 (en)	2010-07-16	2011-07-18	C-met modulator pharmaceutical compositions
PCT/US2011/044378 WO2012009722A1 (en)	2010-07-16	2011-07-18	C-met modulator pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
PL2593090T3 true PL2593090T3 (pl)	2022-02-21

Family

ID=45469828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11740764T PL2593090T3 (pl)	2010-07-16	2011-07-18	Kompozycje farmaceutyczne modulatora c-Met

Country Status (23)

Country	Link
US (10)	US9724342B2 (pl)
EP (2)	EP4014971A1 (pl)
JP (3)	JP5934204B2 (pl)
KR (6)	KR20200029633A (pl)
CN (3)	CN103221035A (pl)
AR (1)	AR082252A1 (pl)
AU (4)	AU2011278950C1 (pl)
BR (1)	BR112013000980B1 (pl)
CA (1)	CA2805645C (pl)
DK (1)	DK2593090T3 (pl)
EA (1)	EA030435B1 (pl)
ES (1)	ES2904646T3 (pl)
HU (1)	HUE057184T2 (pl)
IL (2)	IL224189A (pl)
LT (1)	LT2593090T (pl)
MX (1)	MX336741B (pl)
NZ (1)	NZ607118A (pl)
PL (1)	PL2593090T3 (pl)
PT (1)	PT2593090T (pl)
SG (2)	SG10201609324UA (pl)
TW (3)	TWI619495B (pl)
WO (1)	WO2012009722A1 (pl)
ZA (1)	ZA201300458B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110818633A (zh)	2009-01-16	2020-02-21	埃克塞里艾克西斯公司	一种苹果酸盐及其晶型
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP4014971A1 (en)	2010-07-16	2022-06-22	Exelixis, Inc.	C-met modulator pharmaceutical compositions
FI2621481T4 (fi)	2010-09-27	2023-01-13		Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
CA2826751C (en)	2011-02-10	2021-05-18	Exelixis, Inc.	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en)	2011-04-04	2012-10-04	Exelixis, Inc.	Method of Treating Cancer
MX2013012695A (es)	2011-05-02	2014-03-27	Exelixis Inc	Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
EA201490676A1 (ru)	2011-09-22	2015-02-27	Экселиксис, Инк.	Способ лечения остеопороза
CN110511158A (zh)	2011-10-20	2019-11-29	埃克塞里艾克西斯公司	制备喹啉衍生物的方法
WO2013166296A1 (en)	2012-05-02	2013-11-07	Exelixis, Inc.	A dual met - vegf modulator for treating osteolytic bone metastases
CN103664776B (zh) *	2012-09-26	2016-05-04	正大天晴药业集团股份有限公司	一种酪氨酸激酶抑制剂及其中间体的制备方法
CN105121412B (zh)	2013-03-15	2019-07-12	埃克塞里艾克西斯公司	N-(4-{[6，7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的代谢物
ES2927651T3 (es)	2013-04-04	2022-11-10	Exelixis Inc	Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
CN104370811B (zh) *	2013-08-15	2019-02-12	广东东阳光药业有限公司	一种喹啉化合物的新晶型及其制备方法
CN104649969B (zh) *	2013-11-22	2019-02-12	广东东阳光药业有限公司	一种替尼类药物的盐及其制备方法
CN103751140A (zh) *	2014-01-15	2014-04-30	青岛市肿瘤医院	一种Cabozantinib分散片及其制备方法
CA2939546C (en)	2014-02-14	2023-01-17	Exelixis, Inc.	Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
CN106255499A (zh) *	2014-03-17	2016-12-21	埃克塞里艾克西斯公司	卡博替尼制剂的给药
CN104788372B (zh) *	2014-07-25	2018-01-30	上海圣考医药科技有限公司	一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
US11124481B2 (en)	2014-07-31	2021-09-21	Exelixis, Inc.	Method of preparing fluorine-18 labeled Cabozantinib and its analogs
JP6892381B2 (ja)	2014-08-05	2021-06-23	エグゼリクシス，インコーポレイテッド	多発性骨髄腫を治療するための薬物の組み合わせ
CN105503717A (zh) *	2014-09-24	2016-04-20	江苏奥赛康药业股份有限公司	一种苹果酸卡博替尼化合物及其药物组合物
CA3020749A1 (en) *	2016-04-15	2017-10-19	Exelixis, Inc.	Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CA3021445A1 (en) *	2016-04-19	2017-10-26	Exelixis, Inc.	Triple negative breast cancer treatment method
JP2019529476A (ja)	2016-09-27	2019-10-17	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法
EP3551612A4 (en) *	2016-12-07	2020-08-12	MSN Laboratories Private Limited, R&D Center	PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
MX2019008032A (es)	2017-01-20	2019-12-16	Exelixis Inc	Combinaciones de cabozantinib y atezolizumab para tratar cancer.
AU2018272088C1 (en)	2017-05-26	2022-09-22	Exelixis, Inc.	Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
MX2019015177A (es) *	2017-06-16	2020-02-07	Beta Pharma Inc	Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.
US20190262330A1 (en) *	2017-12-21	2019-08-29	Exelixis, Inc.	Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
CA3088200A1 (en)	2018-01-26	2019-08-01	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
TWI815137B (zh)	2018-06-15	2023-09-11	漢達生技醫藥股份有限公司	尼洛替尼十二烷基硫酸鹽之結晶
WO2020075196A1 (en) *	2018-10-11	2020-04-16	Cipla Limited	Polymorphs of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (s)- malate, methods of production and pharmaceutical uses thereof
WO2021222673A1 (en) *	2020-04-30	2021-11-04	Exelixis, Inc.	Processes for the preparation of a kinase inhibitor
IL302485A (en) *	2020-11-05	2023-06-01	Exelixis Inc	Kinase inhibitor pharmaceutical preparations
US11613630B2 (en)	2020-12-03	2023-03-28	Iowa State University Research Foundation	Solid dry-type lubricant
WO2023122723A1 (en)	2021-12-23	2023-06-29	The Broad Institute, Inc.	Panels and methods for diagnosing and treating lung cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003074497A1 (en)	2002-03-01	2003-09-12	Pintex Pharmaceutical, Inc.	Pin1-modulating compounds and methods of use thereof
ES2371383T3 (es) *	2003-09-26	2011-12-30	Exelixis, Inc.	N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
WO2005046589A2 (en)	2003-11-07	2005-05-26	Chiron Corporation	Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
CA2543650C (en) *	2003-12-25	2010-10-26	Eisai Co., Ltd.	A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
CA2572331A1 (en)	2004-07-02	2006-02-09	Exelixis, Inc.	C-met modulators and method of use
CA2603748A1 (en)	2005-04-06	2006-10-12	Exelixis, Inc.	C-met modulators and methods of use
CA2671982C (en)	2006-12-14	2016-01-26	Exelixis, Inc.	Methods of using mek inhibitors
WO2008083319A1 (en)	2006-12-29	2008-07-10	Il Yang Pharmaceutical Company, Ltd.	Solid state forms of enantiopure ilaprazole
UY31800A (es)	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
TW201035017A (en)	2008-09-26	2010-10-01	Smithkline Beecham Corp	Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
JP5486606B2 (ja)	2008-11-13	2014-05-07	エクセリクシス，インク．	キノリン誘導体の調製方法
US20130030172A1 (en)	2008-12-04	2013-01-31	Exelixis, Inc.	Methods of Preparing Quinoline Derivatives
CN110818633A (zh)	2009-01-16	2020-02-21	埃克塞里艾克西斯公司	一种苹果酸盐及其晶型
WO2011009095A1 (en)	2009-07-17	2011-01-20	Exelixis, Inc.	Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) *	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2475390A4 (en) *	2009-09-09	2014-01-01	Quintiles Transnat Corp	METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
EP2545038A1 (en)	2010-03-12	2013-01-16	Exelixis, Inc.	Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en)	2010-04-16	2012-03-22	Exelixis, Inc.	Methods of Using C-Met Modulators
EP4014971A1 (en)	2010-07-16	2022-06-22	Exelixis, Inc.	C-met modulator pharmaceutical compositions
WO2012009723A1 (en)	2010-07-16	2012-01-19	Exelixis, Inc.	C-met modulator pharmaceutical compositions
JP2013540759A (ja)	2010-09-27	2013-11-07	エクセリクシス，インク．	去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
EP2621483A1 (en)	2010-09-27	2013-08-07	Exelixis, Inc.	Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
FI2621481T4 (fi)	2010-09-27	2023-01-13		Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
CN103327979A (zh)	2010-11-22	2013-09-25	葛兰素史密斯克莱知识产权（第2号）有限公司	治疗癌症的方法
CA2826751C (en)	2011-02-10	2021-05-18	Exelixis, Inc.	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en)	2011-04-04	2012-10-04	Exelixis, Inc.	Method of Treating Cancer
MX2013012695A (es)	2011-05-02	2014-03-27	Exelixis Inc	Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
TW201306842A (zh)	2011-06-15	2013-02-16	Exelixis Inc	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CN110511158A (zh)	2011-10-20	2019-11-29	埃克塞里艾克西斯公司	制备喹啉衍生物的方法

2011
- 2011-07-18 EP EP21202135.6A patent/EP4014971A1/en active Pending
- 2011-07-18 CA CA2805645A patent/CA2805645C/en active Active
- 2011-07-18 CN CN2011800446021A patent/CN103221035A/zh active Pending
- 2011-07-18 HU HUE11740764A patent/HUE057184T2/hu unknown
- 2011-07-18 SG SG10201609324UA patent/SG10201609324UA/en unknown
- 2011-07-18 JP JP2013519870A patent/JP5934204B2/ja active Active
- 2011-07-18 KR KR1020207007177A patent/KR20200029633A/ko active Application Filing
- 2011-07-18 KR KR1020137003043A patent/KR101862324B1/ko active IP Right Review Request
- 2011-07-18 TW TW105119659A patent/TWI619495B/zh active
- 2011-07-18 TW TW100125336A patent/TWI516477B/zh active
- 2011-07-18 MX MX2013000567A patent/MX336741B/es unknown
- 2011-07-18 WO PCT/US2011/044378 patent/WO2012009722A1/en active Application Filing
- 2011-07-18 BR BR112013000980-2A patent/BR112013000980B1/pt active IP Right Grant
- 2011-07-18 TW TW104132637A patent/TW201602083A/zh unknown
- 2011-07-18 ES ES11740764T patent/ES2904646T3/es active Active
- 2011-07-18 KR KR1020197010923A patent/KR20190042768A/ko active Application Filing
- 2011-07-18 PT PT117407643T patent/PT2593090T/pt unknown
- 2011-07-18 KR KR1020227000133A patent/KR20220005631A/ko not_active Application Discontinuation
- 2011-07-18 AU AU2011278950A patent/AU2011278950C1/en active Active
- 2011-07-18 CN CN201610157218.7A patent/CN106420743A/zh active Pending
- 2011-07-18 EA EA201300146A patent/EA030435B1/ru active Protection Beyond IP Right Term
- 2011-07-18 SG SG2013002704A patent/SG187060A1/en unknown
- 2011-07-18 US US13/810,537 patent/US9724342B2/en active Active
- 2011-07-18 NZ NZ607118A patent/NZ607118A/en unknown
- 2011-07-18 PL PL11740764T patent/PL2593090T3/pl unknown
- 2011-07-18 KR KR1020187014254A patent/KR20180056807A/ko active Application Filing
- 2011-07-18 EP EP11740764.3A patent/EP2593090B1/en active Active
- 2011-07-18 AR ARP110102584A patent/AR082252A1/es not_active Application Discontinuation
- 2011-07-18 CN CN202111624430.7A patent/CN114209699A/zh active Pending
- 2011-07-18 LT LTEPPCT/US2011/044378T patent/LT2593090T/lt unknown
- 2011-07-18 KR KR1020217003243A patent/KR20210014770A/ko not_active Application Discontinuation
- 2011-07-18 DK DK11740764.3T patent/DK2593090T3/da active
2013
- 2013-01-13 IL IL224189A patent/IL224189A/en active IP Right Grant
- 2013-01-17 ZA ZA2013/00458A patent/ZA201300458B/en unknown
2016
- 2016-05-06 JP JP2016093433A patent/JP6503317B2/ja active Active
- 2016-10-18 AU AU2016247044A patent/AU2016247044A1/en not_active Abandoned
2017
- 2017-02-07 US US15/426,804 patent/US10039757B2/en active Active
- 2017-06-02 US US15/612,703 patent/US10034873B2/en active Active
- 2017-07-05 IL IL253333A patent/IL253333A0/en unknown
2018
- 2018-07-03 US US16/026,708 patent/US10548888B2/en active Active
- 2018-08-22 AU AU2018220045A patent/AU2018220045B2/en active Active
2019
- 2019-03-25 JP JP2019056131A patent/JP2019142879A/ja not_active Withdrawn
- 2019-12-20 US US16/722,563 patent/US11123338B2/en active Active
2020
- 2020-06-03 AU AU2020203645A patent/AU2020203645A1/en not_active Abandoned
2021
- 2021-08-23 US US17/409,098 patent/US20210379050A1/en not_active Abandoned
- 2021-10-19 US US17/505,307 patent/US20220031688A1/en not_active Abandoned
- 2021-11-30 US US17/538,310 patent/US20220087999A1/en not_active Abandoned
2022
- 2022-07-20 US US17/869,427 patent/US20220370436A1/en not_active Abandoned
2023
- 2023-10-20 US US18/491,407 patent/US20240156804A1/en active Pending

Also Published As

Publication number	Publication date
SG10201609324UA (en)	2017-01-27
TW201602083A (zh)	2016-01-16
AU2020203645A1 (en)	2020-06-25
CA2805645C (en)	2019-05-07
US10034873B2 (en)	2018-07-31
HUE057184T2 (hu)	2022-04-28
US20200121671A1 (en)	2020-04-23
AU2018220045B2 (en)	2020-03-05
KR101862324B1 (ko)	2018-05-29
CN106420743A (zh)	2017-02-22
AU2011278950B2 (en)	2016-07-21
JP2016188215A (ja)	2016-11-04
BR112013000980A2 (pt)	2018-03-13
EA030435B1 (ru)	2018-08-31
JP2013531045A (ja)	2013-08-01
AU2018220045A1 (en)	2018-09-06
NZ607118A (en)	2015-05-29
AU2016247044A1 (en)	2016-11-03
KR20190042768A (ko)	2019-04-24
US20220087999A1 (en)	2022-03-24
AU2011278950A1 (en)	2013-03-07
PT2593090T (pt)	2021-11-04
KR20130137586A (ko)	2013-12-17
EP2593090A1 (en)	2013-05-22
TWI516477B (zh)	2016-01-11
LT2593090T (lt)	2022-01-10
CA2805645A1 (en)	2012-01-19
US20170266178A1 (en)	2017-09-21
ZA201300458B (en)	2013-09-25
EA201300146A1 (ru)	2013-06-28
US20170143689A1 (en)	2017-05-25
US20130337015A1 (en)	2013-12-19
US9724342B2 (en)	2017-08-08
KR20220005631A (ko)	2022-01-13
AU2011278950C1 (en)	2018-11-22
JP5934204B2 (ja)	2016-06-15
KR20210014770A (ko)	2021-02-09
IL253333A0 (en)	2017-09-28
US20240156804A1 (en)	2024-05-16
BR112013000980B1 (pt)	2022-08-16
EP4014971A1 (en)	2022-06-22
US11123338B2 (en)	2021-09-21
EP2593090B1 (en)	2021-10-13
IL224189A (en)	2017-07-31
KR20180056807A (ko)	2018-05-29
US10039757B2 (en)	2018-08-07
AR082252A1 (es)	2012-11-21
US20210379050A1 (en)	2021-12-09
TW201219371A (en)	2012-05-16
TW201735925A (zh)	2017-10-16
US20180311229A1 (en)	2018-11-01
US20220370436A1 (en)	2022-11-24
WO2012009722A1 (en)	2012-01-19
CN103221035A (zh)	2013-07-24
ES2904646T3 (es)	2022-04-05
MX336741B (es)	2016-01-29
JP6503317B2 (ja)	2019-04-17
MX2013000567A (es)	2013-05-01
US10548888B2 (en)	2020-02-04
KR20200029633A (ko)	2020-03-18
TWI619495B (zh)	2018-04-01
SG187060A1 (en)	2013-02-28
JP2019142879A (ja)	2019-08-29
DK2593090T3 (da)	2021-10-25
US20220031688A1 (en)	2022-02-03
CN114209699A (zh)	2022-03-22

Publication	Publication Date	Title
IL253333A0 (en)	2017-09-28	Pharmaceutical preparations that modulate c-met
IL245326A0 (en)	2016-06-30	pharmaceutical preparation
IL223535A (en)	2017-02-28	Solid medicinal compositions
ZA201301766B (en)	2016-11-30	Pharmaceutical compositions
IL225457A0 (en)	2013-06-27	Pharmaceutical composition
ZA201300718B (en)	2013-08-28	Pharmaceutical compositions
ZA201207670B (en)	2013-05-29	Pharmaceutical compositions
ZA201303223B (en)	2014-01-29	Pharmaceutical compositions
GB201010453D0 (en)	2010-08-04	Pharmaceutical composition
ZA201303177B (en)	2018-12-19	Pharmaceutical compositions
IL226554A (en)	2017-12-31	Medicinal preparations containing alisporiovir
GB201001911D0 (en)	2010-03-24	Pharmaceutical composition
EP2560678A4 (en)	2013-09-18	PHARMACEUTICAL COMPOSITIONS
ZA201303732B (en)	2018-12-19	Pharmaceutical compositions
GB201008590D0 (en)	2010-07-07	Pharmaceutical compositions
GB201005403D0 (en)	2010-05-12	Novel pharmaceutical compositions
GB201019775D0 (en)	2011-01-05	Pharmaceutical composition